Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay and evaluation of physiologic variables.

An assay was standardized to measure extrinsic pathway inhibitor (EPI) activity in human plasma. Variables that could potentially influence its measurement were systematically examined. The coefficient of variation of the assay was 6.3% for the same sample assayed on different days. The linear regression line for a plot of observed v expected values of mixtures of plasmas with different EPI levels was Y = 1.01X - 2.7%. Single samples from 21 healthy adults under 60 years of age varied between 74% and 159% of a pooled reference plasma. The plasma level of a given individual (eight subjects) did not vary on repeat sampling over weeks to months. EPI activity was significantly lower in plasma from umbilical cord blood (64.3% +/- 12.7%, n = 16) than in plasma from adults. Mean EPI activity in adults greater than or equal to 60 years of age was slightly but significantly higher (112% +/- 16.8%, n = 23) than in adults less than 60 years of age (97.2% +/- 19.0%, n = 21). EPI levels in the third trimester of pregnancy were slightly higher than in nonpregnant women. Plasma EPI levels fell slightly after surgical procedures that caused fibrinogen levels to rise, which suggests that EPI is not an acute phase reactant. Administration of 1-desamino-8-d-arginine vasopressin (DDAVP) did not alter plasma EPI levels. In two patients subjected to plasmapheresis and volume replacement with albumin and isotonic saline, plasma EPI levels returned to one-half of the levels before pheresis within about one day.

[1]  P. Sandset,et al.  EXTRINSIC PATHWAY INHIBITOR (EPI) DURING ELECTUVE SUGERY : A COMPARISON WITH OTHER COAGULATION INHIBITORS , 1987, Thrombosis and Haemostasis.

[2]  S. Rapaport,et al.  Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. , 1988, Thrombosis and haemostasis.

[3]  M. L. Larsen,et al.  Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). , 1988, Thrombosis research.

[4]  J. Miletich,et al.  Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. , 1988, The Journal of biological chemistry.

[5]  S. Rapaport,et al.  Decreased inducibility of tissue factor activity on human umbilical vein endothelial cells cultured with endothelial cell growth factor and heparin. , 1988, Thrombosis research.

[6]  J. Miletich,et al.  The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action , 1988 .

[7]  James,et al.  The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. , 1988, Blood.

[8]  W. Kisiel,et al.  Evidence that plasma lipoproteins inhibit the factor VIIa-tissue factor complex by a different mechanism that extrinsic pathway inhibitor. , 1987, Blood.

[9]  S. Rapaport,et al.  Affinity purification of human brain tissue factor utilizing factor VII bound to immobilized anti-factor VII. , 1987, Analytical biochemistry.

[10]  P. Sandset,et al.  A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. , 1987, Thrombosis research.

[11]  P. Sandset,et al.  “NEW” COAGULATION INHIBITORS LEVELS IN PNEUMONIA DISSEMINATED INTRAVASCULAR COAGULATION AND LIVER DISEASES , 1987 .

[12]  P. Powers,et al.  Development of the human coagulation system in the full-term infant. , 1987, Blood.

[13]  S. Bajaj,et al.  INHIBITOR OF THE FACTOR VIIA-TISSUE FACTOR COMPLEX IS REDUCED IN PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION BUT NOT IN PATIENTS WITH SEVERE HEPATOCELLULAR DISEASE , 1987, Thrombosis and Haemostasis.

[14]  A. Hubbard,et al.  Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins. , 1987, Thrombosis research.

[15]  J. Miletich,et al.  Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Rapaport,et al.  Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. , 1987, Blood.

[17]  S. Carson,et al.  Tissue factor (coagulation factor III) inhibition by apolipoprotein A-II. , 1987, The Journal of biological chemistry.

[18]  J. Miletich,et al.  Characterization of the inhibition of tissue factor in serum. , 1987, Blood.

[19]  S. Rapaport,et al.  Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. , 1985, Blood.

[20]  S. Bajaj,et al.  Purification of human factor VII utilizing O-(diethylaminoethyl)-Sephadex and Sulfopropyl-Sephadex chromatography. , 1984, Analytical biochemistry.

[21]  S. Bajaj.  Cooperative Ca2+ binding to human factor IX. Effects of Ca2+ on the kinetic parameters of the activation of factor IX by factor XIa. , 1982, The Journal of biological chemistry.

[22]  S. Rapaport,et al.  A simplified procedure for purification of human prothrombin, factor IX and factor X. , 1981, Preparative biochemistry.

[23]  Y. Nemerson,et al.  Kinetics of factor IX activation via the extrinsic pathway. Dependence of Km on tissue factor. , 1980, The Journal of biological chemistry.